 This is a Phase II trial non-randomized study to evaluate the objective response rate and stable disease rate primary endpoints, progression-free survival, overall survival and toxicities with the combination of doxorubicin and bortezomib in patients with incurable head and neck adenoid cystic carcinoma. Also, we plan to collect tumor tissue from previous diagnostic procedures and baseline blood specimens for future correlative studies. 